ArticleAJNR. American journal of neuroradiology2013
Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma.
Article in AJNR. American journal of neuroradiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.Frontiers in medicine · 2022Pooled it
- Standardized uptake value in high uptake area on positron emission tomography with 18F-FRP170 as a hypoxic cell tracer correlates with intratumoral oxygen pressure in glioblastoma.Molecular imaging and biology · 2014Trial
- Diagnostic and Prognostic Value of Hypoxia PET in Glioma: A Systematic Review and Meta-Analysis.Cancers · 2026Review
- Role of [18F]FMISO PET Imaging for the Evaluation of Gliomas: A Comprehensive Literature Review.Diagnostics (Basel, Switzerland) · 2026Review
- Belzutifan for the treatment of renal cell carcinoma.Therapeutic advances in medical oncology · 2025Review
- Unveiling the promising anticancer effect of copper-based compounds: a comprehensive review.Journal of cancer research and clinical oncology · 2024Review
- Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Functional Imaging of Hypoxia: PET and MRI.Cancers · 2023Review
- Advances in PET and MRI imaging of tumor hypoxia.Frontiers in medicine · 2023Review
- [European journal of nuclear medicine and molecular imaging · 2022Article
- Hemodynamic Imaging in Cerebral Diffuse Glioma-Part A: Concept, Differential Diagnosis and Tumor Grading.Cancers · 2022Review
- Review
- Review
- Review
- The cellular basis of increased PET hypoxia tracer uptake in focal cerebral ischemia with comparison between [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
- Imaging of Tumor Hypoxia With Radionuclide-Labeled Tracers for PET.Frontiers in oncology · 2021Review
- Hypoxia imaging and theranostic potential of [EJNMMI research · 2020Review
- Impact of [BMC cancer · 2019Article
- Radionuclide generators: the prospect of availing PET radiotracers to meet current clinical needs and future research demands.American journal of nuclear medicine and molecular imaging · 2019Review
- Contribution of Different Positron Emission Tomography Tracers in Glioma Management: Focus on Glioblastoma.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeHypoxic tissue evaluation in glioma is important for predicting treatment response and establishing antihypoxia therapy. In this preliminary study, (62)Cu-ATSM PET was used to determine its validity as a biomarker for distinguishing tumor grade and tissue hypoxia. MATERIALS AND
methods(62)Cu-ATSM PET was performed in 22 patients with glioma, and the (62)Cu-ATSM SUV(max) and T/B ratio were semiquantitatively evaluated. (62)Cu-ATSM uptake distribution was qualitatively evaluated and compared with MR imaging findings. HIF-1α expression, a hypoxia marker, was compared with (62)Cu-ATSM uptake values.
resultsThe (62)Cu-ATSM SUV(max) and T/B ratio were significantly higher in grade IV than in grade III gliomas (P = .014 and .018, respectively), whereas no significant differences were found between grade III and grade II gliomas. At a T/B ratio cutoff threshold of 1.8, (62)Cu-ATSM uptake was predictive of HIF-1α expression, with 92.3% sensitivity and 88.9% specificity. The mean T/B ratio was also significantly higher in HIF-1α-positive glioma tissue than in HIF-1α-negative tissue (P = .001). Using this optimal threshold of T/B ratio, (62)Cu-ATSM PET showed regional uptake in 61.9% (13/21) of tumors within the contrast-enhanced region on MR imaging, which was significantly correlated with presence of a necrotic component (P = .002).
conclusionsOur results demonstrated that (62)Cu-ATSM uptake is relatively high in grade IV gliomas and correlates with the MR imaging findings of necrosis. Moreover, the (62)Cu-ATSM T/B ratio showed significant correlation with HIF-1α expression. Thus, (62)Cu-ATSM appears to be a suitable biomarker for predicting highly malignant grades and tissue hypoxia in patients with glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.